BMS Advances Cardiovascular Growth Plans With Milvexian, Camzyos Milestones

 
• By Mandy Jackson

Bristol and Janssen detailed the now under way Phase III program for Factor XIa inhibitor milvexian and BMS shared data at ACC to help prescribers get comfortable with Camzyos, launched last year.

Human heart anatomy form lines and triangles, point connecting network on blue background.
Camzyos launched last year; milvexian is entering Phase III • Source: Shutterstock

More from Clinical Trials

More from R&D